Innova Captab Ltd
NSE: INNOVACAP BSE: 544067Pharma
Incorporated in January 2005, Innova Captab Ltd is a pharmaceutical company is an integrated pharmaceutical company in India with a presence across the pharmaceutical value chain.[1]
₹878
52W: ₹608 — ₹1021
PE 60 · Book ₹155 · +466% vs bookMarket Cap₹5,023 Cr
Stock P/E60Price to Earnings
ROCE10.8%Return on Capital
ROE9.85%Return on Equity
Div. Yield0.23%Face Value ₹10
Strengths
- +Company is expected to give good quarter
Weaknesses
- −Stock is trading at 5.74 times its book value
- −Company has a low return on equity of 11.5% over last 3 years.
- −Company might be capitalizing the interest cost
Shareholding Pattern
Promoters50.9%
FIIs0.23%
DIIs20.14%
Public28.74%
| Category | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 50.9% | 50.9% | 50.9% | 50.9% | 50.9% | 50.9% | 50.9% | 50.9% |
| FIIs | 1.19% | 1.01%▼0.2 | 0.74%▼0.3 | 0.35%▼0.4 | 0.23%▼0.1 | 0.08%▼0.2 | 0.1%▲0.0 | 0.23%▲0.1 |
| DIIs | 21.24% | 20.61%▼0.6 | 19.96%▼0.6 | 19.77%▼0.2 | 19.67%▼0.1 | 20.17%▲0.5 | 20.24%▲0.1 | 20.14%▼0.1 |
| Public | 26.67% | 27.48%▲0.8 | 28.41%▲0.9 | 29%▲0.6 | 29.2%▲0.2 | 28.86%▼0.3 | 28.76%▼0.1 | 28.74%▼0.0 |
Financial Statements
| Metric | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 236 | 198 | 227 | 240 | 249 | 243 | 287 | 290 | 364 | 358 |
| Expenses | 206 | 175 | 198 | 207 | 216 | 214 | 252 | 260 | 317 | 320 |
| Operating Profit | 31 | 23 | 28 | 33 | 32 | 28 | 35 | 29 | 47 | 39 |
| OPM % | 13% | 12% | 13% | 14% | 13% | 12% | 12% | 10% | 13% | 11% |
| Net Profit | 19 | 20 | 22 | 26 | 24 | 17 | 20 | 14 | 28 | 21 |
| EPS ₹ | 3.26 | 3.45 | 3.9 | 4.48 | 4.26 | 2.99 | 3.55 | 2.5 | 4.88 | 3.7 |
AI Insights
Revenue Trend
Mar 2026 revenue at ₹1,299Cr, up 35.6% YoY. OPM at 12%.
Debt Position
Borrowings at ₹321Cr. Debt-to-equity ratio: 0.39x. Healthy balance sheet.
Capex Cycle
CWIP at ₹15Cr (2% of fixed assets). Moderate ongoing capital expenditure.
Institutional Flow
DIIs: 20.14% (+9.83pp change). FIIs: 0.23% (-3.34pp change). Promoters hold 50.9%.
Margin & Efficiency
ROCE improving from 0% (Mar 2020) to 11% (Mar 2026). Working capital days: 94.
Valuation
PE 60x with 10.8% ROCE. Price is 466% above book value of ₹155. Dividend yield: 0.23%.
Recent Announcements
- Announcement under Regulation 30 (LODR)-Earnings Call Transcript 14 May - This is in continuation to our letter dated 08th May, 2026, wherein we had informed regarding the audio link of the earnings call with analysts/investors …
- Announcement under Regulation 30 (LODR)-Newspaper Publication 8 May - Board of the Company at its meeting held on Thursday, 7th May, 2026, has approved the Audited (Standalone and Consolidated) Financial result of the Company …
- Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 8 May - Audio recording of 8 May 2026 earnings call for Q4 and FY2026 results uploaded.
- Announcement under Regulation 30 (LODR)-Investor Presentation 7 May - This is in continuation to our dated 30th April, 2026 wherein we had informed regarding an earnings call Scheduled to be held on Friday 08th …
- Announcement under Regulation 30 (LODR)-Press Release / Media Release 7 May - Innova Captab reported Q4 FY26 revenue of ₹447.8 crore and FY26 revenue of ₹1,630 crore.
- Financial Year 2025 from bse
- Financial Year 2024 from bse
- Rating update 17 Apr from care